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Abstract
Background: The central-line associated bloodstream infections (CLABSI) are the most common healthcare-
associated infections in childhood. Despite the international data available on healthcare-associated infections in
selected groups of patients, there is a lack of large and good quality studies. The present survey is the first
prospective study monitoring for 6 months the occurrence of central-line associated bloodstream infections in all
departments of an Italian tertiary care children’s university hospital.
Methods: The study involved all children aged less than 18 years admitted to Meyer Children’s University Hospital,
Florence, Italy who had a central line access between the October 15th, 2014 and the April 14th, 2015. CLABSI
were defined according to the Center for Disease Control and Prevention criteria. CLABSI incidence rates with
95% confidence limits were calculated and stratified for the study variables. For each factor the relative risk and
95% confidence intervals were evaluated. Statistical analysis was performed using the statistical software SPSS for
Windows, version 22.0 (SPSS Inc., Chicago, IL), p < 0.05 was considered statistically significant.
Results: CLABSI rate was 3.73/1000 (95% CI: 2.54–5.28) central line-days. A higher CLABSI incidence was seen
with female gender (p = 0.045) and underlying medical conditions (excepting prematurity, surgical diseases and
malignancy) (p = 0.06). In our study 5 infections, were caused by extended-spectrum β-lactamase producing
organisms and in one case by carbapenem-resistant Klebsiella pneumoniae.
Conclusions: Our study confirms the spreading of multi-resistant pathogens as causes of healthcare associated
infections in children. An increased incidence rate of CLABSI in our study was related to underlying medical
conditions. Pediatric studies focusing on healthcare infections in this type of patients should be done in order to
deepen our understanding on associated risk factors and possible intervention areas.
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Background
The central line associated bloodstream infections
(CLABSI) are the most common healthcare-associated
infections (HAIs) in childhood. The results of the
International Nosocomial Infection Control Consortium
surveillance study from January 2007 to December 2012
in pediatric intensive care units (PICU) in Latin America,
Asia, Africa and Europe, showed CLABSI rate of 6.1/1000
(95% CI: 5.7–6.5) central line-days [1]. The 2014 report of
the European Centre for Disease Prevention and Control
(ECDC) estimated a mean device-adjusted rate in patients
staying in an ICU for more than two days was 3.0 CLABSI
episodes per 1000 central line-days (IQR: 0.5–4.1) [2]. A
cohort study performed from 2007 to 2012 in 173 neo-
natal intensive care unit (NICU) and 64 PICU reporting
data to the Centers for Disease Control and Prevention’s
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National Healthcare Safety Network in United States,
showed a reduction of CLABSI rates from 4.9 to 1.5/1000
central line-days in NICU and from 4.7 to 1.0/1000 central
line-days in PICU in 5 years time [3]. A trend of infection
rate reduction was seen also in a prospective 2-year quality
improvement British project conducted in 21 PICU with
overall 34,635 central line-days analyzed [4].
Despite the international data available on HAIs in se-
lected groups of patients, there is a lack of large and
good quality studies. The best methodology to obtain re-
liable data would be a continuous prospective study.
However, this type of study would require dedicated staff
and enormous financial resources. Short prospective
study or Point-prevalence survey are possible strategies.
In the first case, data are collected about a certain period
of time, giving a good estimate of the global burden and
being cost-saving. The point-prevalence survey gives a
punctiform picture (usually a day), allows collecting data
in an easy and low-cost way but it is less accurate than
the previous method. A Canadian point-prevalence survey
was done on about 1353 pediatric patients with central-line
access or with assisted-ventilation. Data were collected for
24 h in 30 hospitals. One hundred-eighteen patients (8.7%)
had a HAI, of those 38 events (30.7%) were CLABSI [5]. A
prospective study performed in 29 NICU in United States
between October 2006 and December 2007 found that
the risk of CLABSI is very low during the first week of
catheterization and especially with lines inserted in the
jugular vein, whereas it is increased in oncological and
gastrointestinal patients and in case of prolonged
catheterization [6]. Further recent studies estimated
that CLABSI results in additional hospital costs on a
per-case basis of 45,000 dollars [7–9]. The available
studies are usually limited to selected groups of pa-
tients as oncological children or patients admitted to
PICU. There are few prospective studies performed in a
whole hospital in order to investigate the global inci-
dence of HAIs. A Swiss study performed in a single in-
stitution between April 2008 and March 2009 on 152
patients showed an overall CLABSI incidence of 0.95/
1000 central line-days. In this study, CLABSI incidence
varied by type of catheter and by patient’s age, with the
highest risk in neonates with Silastic® percutaneous
central line [10].
Available data regarding children’s HAIs in Italy are
limited to selected group of patients. A study done in
Naples on 120 oncologic children found a positivity of
blood cultures from central line in about one third
(28.3%; 128/425 samples) of cases clinically suspected
for infection [11]. There are two prospective studies
performed in Turin: the first included 748 oncologic or
immunologic patients within 7 years, registering 174
episodes of CLABSI [12], whereas the second enrolled
153 children with previous cardio-surgery, founding a
CLABSI incidence of 11.7/1000 central line-days [13].
The only point-prevalence survey available in the Italian
pediatric population was set in a large tertiary care chil-
dren’s hospital in Rome between 2007 and 2010. A
two-weeks period monitoring was performed each year
of the study, with 1506 patients included. Overall, 102
(6.8%) HAIs were identified, one third of which were
CLABSI [14].
The present study is the first prospective study monitor-
ing for 6 months the occurrence of CLABSI in all depart-
ments of a tertiary care children’s University hospital.
Methods
Study setting
The Meyer Children’s University Hospital is a 198-bed
tertiary care university hospital in Florence, Italy. It is
the Tuscany Region Pediatric Hospital, but one fourth of
children come from other Italian Regions or from
abroad. The hospital is structured for intensity of care,
with two intensive care units (NICU and PICU), and
Departments of oncology, surgery, neuroscience unit
(including also neurosurgery patients) and a bone mar-
row transplant unit. Moreover, there are two medical
wards for 14 pediatric medicine sub-specialties, and an
unit for elective specialty admissions. The annual hospital
inpatient admissions were 8898 in 2014, for overall 53,988
admission-days.
Study population
The study involved prospectively children aged less than
18 years admitted to Meyer Children’s University Hos-
pital who had a central line access inserted between the
October 15th 2014 and April 14th 2015.
Data collection
During the study period the global number of children
admitted to the hospital was monitored daily and the pa-
tients meeting the inclusion criteria were enrolled in the
study. The data were collected daily by the trained
healthcare staff involved in hospital infection control.
Ethical approval was not required because the survey
was carried out for surveillance purposes according to
the criteria of hospital good clinical practice. The sur-
veillance of CLABSI was performed in all the intensive
care, medical, surgical and neonatal wards. The data
were collected using a standardized format. The data
were collected anonymously and entered in the study
database, following the international guidelines for data
protection.
For each child the following data were entered into the
study database: demographic data, reason for admission,
underlying illness, type of device, antibiotic treatment.
Reasons to stop the follow-up were: hospital discharge,
device removal or infection event related to the device.
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Clinical, hematological and microbiological criteria for
diagnosis were recorded in case of infection. The pathogen
identified was also documented.
Case definitions
CLABSI were defined according to the Center for Disease,
Control and Prevention (CDC) criteria [15]. CLABSI are
defined as laboratory-confirmed bloodstream infection
where central line or umbilical catheter was in place for
>2 calendar days on the date of event and the line was in
place on the date of event or the day before [15]. In order
to capture data only about infections acquired during the
hospitalization, the definition of CLABSI was considered
valid only if the positive blood culture and clinical signs/
symptoms of infection occurred after at least 48 h from
admission.
Statistical analysis
Median and interquartile range (IQR) was calculated for
continuous measurement in the study groups (i.e., age).
Categorical data were compared using the Chi-squared
test (or Fisher’s exact test, when expected cell sizes were
smaller than five). CLABSI incidence rates with 95%
confidence limits were calculated and stratified for the
study variables. Specifically, the variables included in the
analysis were: age, gender, underlying illness, type of de-
vice, treatment. For each factor the relative risk (RR) and
95% confidence intervals (95% CI) were evaluated. Statis-
tical analysis was performed using the statistical software
SPSS for Windows, version 22.0 (SPSS Inc., Chicago, IL),
p < 0.05 was considered statistically significant.
Results
Overall, 388 children with central line access were en-
rolled during their hospital stay, resulting in 7783 catheter
observation-days. The median age was 21 months (IQR:
3–105.5). The underlying conditions of the children en-
rolled in the study were: medical (n = 135, 34.8%), onco-
logical (n = 118, 30.4%), surgical (n = 116, 29.9%) and
prematurity (n = 19, 4.9%). Median catheter dwell time
during hospital admission was 4 days (IQR: 2–9).
During the study period there were 29 episodes of
CLABSI in 26 patients. In particular, two children had
respectively 2 and 3 infections during the observation
period. The characteristics of the children with CLABSI
are reported in Table 1.
The global incidence of CLABSI was 3.73/1000 (95%
CI: 2.54–5.28) central line-days.
The risk of infection in our study population was sig-
nificantly correlated to female gender (RR = 2.17, 95%
CI: 1.02–4.86, p = 0.045). Considering the catheter type,
the incidence of CLABSI appeared higher for Broviac
and short-term catheters, resulting almost double than
Port-a-Cath and peripherally inserted central catheters
(PICC). This difference could be explained because in
our setting PICC are used mostly for antibiotic treat-
ment compared to Broviac catheters which are mainly
used for parenteral nutrition and in oncology patients.
The highest rate of CLABSI resulted in children with
an underlying medical condition (i.e., respiratory, renal
or cardiac diseases, neurological or metabolic condi-
tions). In this group of patients, the number of infections
were 16 for 2951 central line-days, with an incidence
rate of 5.42/1000 catheter-days (IQR 3.10–8.80) and a
RR of 2.01 (95% CI: 0.96–4.28), p = 0.06. The risk of
CLABSI was significantly higher in patients within the
respiratory sub-group compared to all the other condi-
tions (RR = 4.38, 95% CI: 1.30–11.74, p = 0.021). Patients
admitted to intensive care unit and to medical wards
had a higher rate of infection (respectively 5.42 and
5.69/1000 catheter-days) compared with the other units;
however, this result was not statistically significant. The
Table 1 Characteristics of the 26 children with CLABSI during
the study period
Age (months), median [IQR] 11.5 [4–37]
Gender, n (%)
- Male 10 (38.5)
- Female 16 (61.5)
Underlying disease, n (%)
- Medical 15 (57.7)
- Oncological 6 (23.1)
- Surgical 4 (15.4)
- Neonatological 1 (3.8)
Catheter type, n (%)a
- Port-a-Cath 2 (6.9)
- PICC 3 (10.4)
- Short term 11 (37.9)
- Broviac 13 (44.8)
Catheter days, median [IQR] 13 [4–20]
Ward, n (%)a
- ICU 9 (31)
- NICU 4 (13.8)
- Medical wards 9 (31)
- Oncology 4 (13.8)
- Neurology and Neurosurgery 1 (3.5)
- Surgery 2 (6.9)
Treatment, n (%)a
- Yes 24 (82.8)
- No 2 (6.9)
- Unknown 3 (10.3)
IQR interquartile range, PICC peripherally inserted central catheters, ICU
intensive care unit, NICU neonatal intensive care unit
acalculated on the total number of CLABSI event (n = 29)
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incidence of CLABSI by population characteristics is re-
ported in Table 2.
In more than half of the patients the pathogens iden-
tified were Enterobacteriaceae and Candida spp. The
complete list of the microorganisms found is displayed
in Fig. 1.
Discussion
The present study is designed to assess the incidence
rate of CLABSI in a whole pediatric children tertiary
care hospital in a 6-months prospective surveillance. In
our study CLABSI rate is 3.73/1000 (95% CI: 2.54–5.28)
central line-days. Comparing studies on CLABSI is chal-
lenging due to different study population and method-
ology used. Only another prospective study, conducted
in a whole pediatric hospital, is available in literature
[10]. This study included 152 patients for overall 14,752
catheter observation days, with a CLABSI rate of 0.95/
1000 central line-days [10]. This lower CLABSI rate
should be interpreted considering that, differently from
our survey, Wagner and colleagues enrolled mainly neo-
natal, hematological/oncological and surgical patients. If
we consider only these types of patients in our study,
the CLABSI rate decreases to 2.69/1000 catheters-days
(95% CI: 1.43–4.60). Moreover, the authors concluded
that the heterogeneous case mix of the patients enrolled,
including also out-patients settings, accounts for the low
CLABSI rate found [10]. On the contrary, our study is
conducted on inpatients only; therefore, the case mix
index of our study population could be estimated on the
basis of the average diagnosis-related group (DRG)
weight, which was 1.48 in 2014.
Moreover, the present study can be compared with
two previous one-month prospective surveys carried out
in 2012 and in 2013 in our tertiary-care children’s uni-
versity hospital [16]. The data collected were respectively
Table 2 Distribution of CLABSI incidence by population characteristics






- ≤ 1 year 3196 14 4.38 2.39, 7.35
- >1 year 4587 15 3.27 1.83, 5.39
Gender:
- Male 4149 10 2.41 1.15, 4.43
- Female 3634 19 5.23 3.15, 8.16
Underlying disease:
- Medical 2951 16 5.42 3.10, 8.80
- Oncological 2923 8 2.74 1.18, 5.39
- Surgical 1577 4 2.54 0.68, 6.49
- Neonatological 332 1 3.01 0.04, 16.76
Catheter type:
- Port-a-Cath 775 2 2.58 0.29, 9.32
- PICC 1269 3 2.36 0.47, 6.90
- Short term catheter 2432 11 4.52 2.25, 8.09
- Broviac 2959 13 4.39 2.34, 7.51
- Umbilical vein catheter 105 0 – –
- Unknown 243 0 – –
Ward:
- ICU 1660 9 5.42 2.47, 10.29
- NICU 1377 4 2.90 0.78, 7.44
- Medical ward 1581 9 5.69 2.60, 10.81
- Oncology and BMT 2015 4 1.98 0.53, 5.08
- Neurology and Neurosurgery 449 1 2.23 0.03, 12.39
- Surgery 587 2 3.41 0.38, 12.30
- Speciality ward 114 0 – –
CI confidence interval, CLABSI central-line associated bloodstream infections, PICC peripherally inserted central catheter, ICU intensive care unit, NICU neonatal
intensive care unit, BMT bone marrow transplant
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on 97 children with CLABSI (935 central line-days) in
2012 and on 122 children (1123 central line-days) in
2013. CLABSI incidence rate found in the two reports
was respectively 3.21/1000 catheter days (95% CI: 1.03–
9.95) in 2012 and 1.78 (95% CI: 0.45–7.12) in 2013 [16].
CLABSI incidence rate find in the present study almost
overlaps with the one found in 2012 survey, but it re-
sults higher than the 2013 ones. This fact is probably
due to the increasing case mix of our hospital, object-
ively documented by hospital DRG, as explained above.
However, an important limitation of the previous sur-
veys performed in our hospital was the short length of
the study, which explains the wide confidence intervals
obtained and may justified this difference.
In 2012, our hospital participated to the point preva-
lence survey coordinated by the ECDC, resulting to have
a prevalence of HAIs of 8% (LC 95% 3.9–14.1), 9.1% of
those were CLABSI (prevalence 1.8%, 95% CI −0,7–4.2%)
[17]. On the other hand, the rate of HAIs in our hospital
in 2014 was retrospectively estimated on the basis of
laboratory-derived microbiological isolates, resulting 5.6/
1000 hospital stay-days (300 infections during 53,988 days
of hospitalization, 95% CI 4.9–6.2). Specifically, the
analysis of microbiological data showed 39 positive
blood cultures in children with central line access, with
a CLABSI incidence of 0.51/1.000 central line-days
(7605 central line- day, estimated by the prospective
study), lower than the incidence of 3.4/1.000 central
line-days in 2013. However, the retrospective method-
ology might underestimate the incidence of CLABSI.
Interestingly, our study points the attention on
underlying medical conditions as an important risk fac-
tor for developing CLABSI. In the available literature
this type of patients was poorly studied, as the attention
focused mainly on intensive care and oncological patients
[1, 3, 4, 6, 11, 12]. However, in this wide group are in-
cluded children with high risk of developing catheter
related infections for different reasons. For example,
in gastroenterological disorders (i.e., short bowel syn-
drome or inflammatory bowel disease), the parenteral
nutrition was seen to be an adjunctive risk for infec-
tions [10, 18]. Unfortunately, this information has not
been collected in our study. Moreover, in chronic dis-
orders as renal diseases (chronic renal failure, dialysis
patients), chronic respiratory conditions (bronchodysplasia,
congenital tracheobronchial anomalies) and metabolic
diseases the infection risk might be increased by possible
immunosuppressive mechanisms in these chronic diseases.
Moreover, patients with polymalformative syndromes might
require multiple devices for enteral feeding and respiratory
support. These conditions could increase the risk of
bacteremia and catheter colonization. The risk of infection
seems to be particularly higher in the sub-group of respira-
tory patients. This might be related to the complexity of
these patients, who might require a superior intensity of
care [19–21].
Fig. 1 Microorganisms identified in children with CLABSI. The complete list of the microorganisms found is displayed in the figure. The pathogens
isolated in patients with CLABSI are mainly Enterobacteriaceae and Candida spp. Five infections, out of the 9 cases caused by Enterobactriaceae
identified are due to extended-spectrum β-lactamase producing organisms (3 Escherichia coli, 2 Klebsiella pneumoniae) and in one case by
carbapenem-resistant Klebsiella pneumoniae. Specifically, Candida albicans has been identified in 5 (71.4%) patients and Candida parapsilosis in
other 2 (28.6%) children
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The risk of developing CLABSI in our study population
is almost double in patient with Broviac and short term
catheters compared to Port-a-Cath and PICC. Despite few
pediatric studies available on CLABSI incidence in pa-
tients with PICC [19, 21], studies directly comparing dif-
ferences by catheter type are limited [10, 22]. Moreover,
comparison of unrelated studies is difficult because of het-
erogeneity in study populations and study methods [23].
Large pediatric prospective studies focuses on identifying
the device with lower infections rate are needed.
The pathogens isolated in patients with CLABSI are
mainly Enterobacteriaceae and Candida spp. Enterobac-
teriaceae spread is an emergent cause of severe infec-
tions. These pathogens are of increasing concern due to
the rise of carbapenem resistance, which has created a
generation of organism resistant to multiple antibiotic
classes [24]. In Italy, gram negative resistance rate to
third generation cephalosporins is between 30 and 56%
[25], whereas the rate of carbapenem resistant Klebsiella
is around 34% in invasive infections [26]. There is a lack
of prevalence data in pediatric patients.
In our study 5 infections, out of the 9 cases identified
are caused by extended-spectrum β-lactamase producing
organisms (3 Escherichia coli, 2 Klebsiella pneumoniae)
and in one case by carbapenem-resistant Klebsiella
pneumoniae. In our surveillance no methicillin resistant
Staphylococcus aureus nor vancomycin resistant Entero-
coccus infections were detected. The CLABSI caused by
Candida spp. are beyond the neonatal period thanks to
the spreading use of fluconazole prophylaxis. Specifically,
Candida albicans has been identified in 5 (71.4%) patients
and Candida parapsilosis in other 2 (28.6%) children.
Regarding CLABSI rate, our study is designed to assess
the incidence rate during patients’ hospital admission.
Therefore, our results could not be extrapolated as an
overall CLABSI incidence for each central line implanted,
as this rate might differ if the follow-up was extended to
the outpatient clinics and to the home-care. Moreover,
our results might not necessarily reflect the HAIs inci-
dence of other Italian hospitals because of different set-
tings and case complexity. Monitoring HAIs is the best
way to assess the risk factors for infection globally and
specifically for each institution. Moreover, it helps in
planning preventive interventions to reduce patient’s
morbidity and mortality, to save costs and to control
resistant-microorganisms spread. Point prevalence sur-
veys are cheaper and easier to conduct than long pro-
spective studies, but might underestimate the real risk.
Cost-effectiveness balance should be done to choose
the best monitoring strategy for each setting.
Conclusions
Our study confirms the spreading of multi-resistant
pathogens as causes of healthcare associated infections
in children. An increased incidence rate of CLABSI in
our study was related to underlying medical conditions.
Pediatric studies focusing on healthcare infections in this
type of patients should be done in order to deepen our
understanding on associated risk factors and possible
intervention areas.
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